文献速递泌尿男性生殖肿瘤支持与姑息治疗

转移性去势抵抗性前列腺癌患者健康相关生活质量评分与临床结局的关联:AFFIRM与PREVAIL研究的探索性分析

The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies.
PubMed 文献 · Eur J Cancer · 2017-10-31

该探索性分析基于AFFIRM与PREVAIL两项III期试验,评估转移性去势抵抗性前列腺癌(mCRPC)患者健康相关生活质量(HRQoL)基线及随时间变化与总生存(OS)和影像学无进展生存(rPFS)的关联。结果显示,多个基线HRQoL领域可预后rPFS和OS,且该关联在治疗期间持续存在,提示HRQoL变化对患者预期生存具有信息价值。

要点

  • 基线及时间依赖性分析中,多个HRQoL指标与OS独立相关
  • FACT-P总分每改善10分,AFFIRM与PREVAIL的死亡风险分别降低19%与21%
  • rPFS仅与部分HRQoL领域相关,HRQoL变化可提示预期生存

核心结论

  • 多个基线HRQoL领域可预后mCRPC患者的rPFS和OS,且该关联在治疗期间持续存在,提示HRQoL变化对患者预期生存具有信息价值。

研究设计与样本

  • AFFIRM(NCT00974311)与PREVAIL(NCT01212991)两项III期试验的探索性分析,比较恩扎卢胺与安慰剂,分别纳入化疗后与化疗初治的mCRPC患者。
  • HRQoL采用FACT-P量表评估,多因素分析评估基线及时间依赖性评分的预后意义,并校正治疗及临床/人口学变量。
  • 以风险比(HR)及95%置信区间(CI)表示HRQoL变量每变化一个最小重要差异(MID)对应的rPFS或OS风险。

主要发现

  • 时间依赖性分析中,FACT-P总分增加(改善)10分与死亡风险降低相关:AFFIRM为19%(HR 0.81 [95% CI 0.78-0.84]),PREVAIL为21%(HR 0.79 [0.76-0.83])。
  • 基线分析中,FACT-P总分增加10分与死亡风险降低相关:AFFIRM为12%(HR 0.88 [0.84-0.93]),PREVAIL为10%(HR 0.90 [0.86-0.95])。
  • 基线与时间依赖性多因素分析中,OS在两个研究中均与多个HRQoL指标独立相关;rPFS在两个研究中均与部分HRQoL领域相关。

临床怎么用

  • 在mCRPC患者管理中可结合FACT-P等HRQoL评分辅助预后判断,并动态关注HRQoL变化以提示预期生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Our exploratory analysis examined the association between health-related quality of life (HRQoL) (baseline and change over time) and clinical outcomes (overall survival [OS]/radiographic progression-free survival [rPFS]) in metastatic castration-resistant prostate cancer (mCRPC). METHODS: HRQoL, OS and rPFS were assessed in phase III trials comparing enzalutamide with placebo in chemotherapy-naïve (PREVAIL; NCT01212991) or post-chemotherapy (AFFIRM; NCT00974311) mCRPC. HRQoL was assessed using the Functional Assessment of Cancer Therapy-Prostate (FACT-P). Multivariate analyses evaluated the prognostic significance of baseline and time-dependent scores after adjusting for treatment and clinical/demographic variables. Hazard ratios (HRs) and 95% confidence intervals (CIs) represented the hazard of rPFS or OS per minimally important difference (MID) score change in HRQoL variables. RESULTS: In baseline and time-dependent multivariate analyses, OS was independently associated with multiple HRQoL measures across both studies. In time-dependent analyses, a 10-point (upper bound of MID range) increase (improvement) in FACT-P total score was associated with reductions in mortality risk of 19% in AFFIRM (HR 0.81 [95% CI 0.78-0.84]) and 21% in PREVAIL (HR 0.79 [0.76-0.83]). For baseline analyses, a 10-point increase in FACT-P total score was associated with reductions in mortality risk of 12% (HR 0.88 [0.84-0.93]) and 10% (HR 0.90 [0.86-0.95]) in AFFIRM and PREVAIL, respectively. rPFS was associated with a subset of HRQoL domains in both studies. CONCLUSION: Several baseline HRQoL domains were prognostic for rPFS and OS in patients with mCRPC, and this association was maintained during treatment, indicating that changes in HRQoL are informative for patients' expected survival.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Beer TM, Miller K, Tombal B, et al. The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies. Eur J Cancer. 2017. PMID: 29096157. doi:10.1016/j.ejca.2017.09.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。